Additionally, HR-positive breast cancers, which initially responded well to hormone therapy, can develop into recurrent tumors with downregulation or loss of ER or PR, a finding which may contribute to resistance to endocrine therapy and highlights the challenges associated with breast cancer treatment [4,5,6]. The gene discussed is PGR; the disease is breast carcinoma.